Navigation Links
Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology
Date:7/27/2011

HUNT VALLEY, Md., July 27, 2011 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a leading contract development and manufacturing organization, today announced  that it has added hot melt extrusion (HME) to its portfolio of formulation and process development solutions. The company has purchased a 16mm and an 18mm Leistritz twin screw extruders. This investment enables Pii to carry out feasibility studies, using just a few grams of active pharmaceutical ingredient, to pilot scale cGMP productions for Phase I and II clinical trials using HME.

A well known processing technology, hot melt extrusion offers a number of benefits to optimize drug formulation, including the development of solid dispersions for bioavailability enhancement of poorly soluble compounds and controlled release drug delivery.

"Pii's investment in hot melt extrusion is part of the company's goal of providing our clients with a comprehensive package of bioavailability enhancement capabilities," said Steve King, senior vice president of Pii. "This proven technology further enables us to meet the challenges of poorly soluble compounds and advance our client's compounds through the development pipeline."

In addition to the new hot melt extrusion capability, Pii's solutions for bioavailability enhancement include spray drying, solvent-based fluid bed processing, soft gels and liquid filled hard capsules.

About Pharmaceutics International, Inc.

Pharmaceutics International, Inc. (Pii) is a privately held Drug Delivery Solutions company providing dosage form development and GMP Manufacturing services to the global pharmaceutical industry. Pii's vision is to become the benchmark in pharmaceutical product development outsourcing. Headquartered in Hunt Valley Maryland USA with European facilities in the UK, Pii offers preformulation testing, formulation development and clinical trial material and commercial manufacture of parenteral, solid, semi-solid and liquid dosage forms. For further information about Pii visit www.pharm-int.com.

Contact:
Elizabeth Hickman, Marketing Manager
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (443) 858-0768
Email: ehickman@pharm-int.com


'/>"/>
SOURCE Pharmaceutics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutics International Inc. (Pii) Announces Appointment of Rampurna Prasad Gullapalli, Ph.D. as Vice President of Drug Delivery Technologies
2. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
3. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
4. Chindex International, Inc. Reports First Quarter 2011 Financial Results
5. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2010
6. Chindex International, Inc. Reports Financial Results for the Three and Nine Month Period Ended December 31, 2010
7. VWR International, LLC Acquires AMRESCO Inc.
8. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
9. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
10. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
11. HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
Breaking Medicine News(10 mins):